secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001213900-25-072814
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M
---------------------------------------------------------------------------

- Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.
- Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.
- Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.
- Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.
- Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/0001213900-25-072814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea0252043-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-072814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer